|
French Pathway for Off-Label Prescribing Increases Scrutiny, While Allowing Access
Recent measures in France will broaden risk-benefit scrutiny and expand off-label drugs use in justifiable situations, according to an opinion piece in the Oct. 4 issue of The New England Journal of Medicine.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives